Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin

British Journal of Dermatology

Volumn 156, Issue 5, 2007, Pages 1020-1026

  Stander S ^a   Stander H ^a   Seeliger, S ^a   Luger, T A ^a   Steinhoff, M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Burning; Calcineurin inhibitor; Pruritus; Sensory neuron; Transient receptor potential vanilloid 1

Indexed keywords

CALCINEURIN INHIBITOR; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; HISTAMINE; HISTAMINE RECEPTOR; NEUROPEPTIDE; PIMECROLIMUS; PROTEINASE ACTIVATED RECEPTOR 2; SUBSTANCE P; TACROLIMUS; TRYPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPLICATION SITE BURNING; APPLICATION SITE PRURITUS; ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; IMMUNOFLUORESCENCE; INFLAMMATION; MAST CELL DEGRANULATION; MEDIATOR; MICROSCOPY; MOUSE; NONHUMAN; OINTMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INDUCTION; PROTEIN SECRETION; RECEPTOR BINDING; SENSORY NERVE; SKIN; SKIN IRRITATION; SKIN TOXICITY; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ANIMALS; CELL DEGRANULATION; DERMATITIS, CONTACT; IMMUNOSUPPRESSIVE AGENTS; MAST CELLS; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEUROPEPTIDES; OINTMENTS; SKIN; SUBSTANCE P; TACROLIMUS;

EID: 34247401321     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07813.x     Document Type: Article

References (17)

1. Alomar A, Berth-Jones J, Bos JD et al. European Working Group on Atopic Dermatitis. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004 151 (Suppl. 70 3 27.
2. Tomi NS, Luger TA. The treatment of atopic dermatitis with topical immunomodulators. Clin Dermatol 2003 21 : 215 24.
3. Ständer S, Schürmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther and Clin Risk Manag 2006 2 : 213 18.
4. Reitamo S, Wollenberg A, Schöpf E et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000 36 : 999 1006.
5. Soter NA, Fleischer AB Jr., Webster GF et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001 44 (Suppl. 1 S39 46.
6. Paller A, Eichenfield LF, Leung DY et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001 44 (Suppl. 1 S47 57.
7. Kang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001 44 (Suppl. 1 S58 64.
8. Luger T, van Leent EJM, Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001 144 : 788 94.
9. Meurer M, Folster-Holst R, Wozel G et al. CASM-DE-01 Study Group. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002 205 : 271 7.
10. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002 46 : 495 504.
11. Wahn U, Bos JD, Goodfield M et al. Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 110 : 1 8.
12. Seeliger S, Derian CK, Vergnolle N et al. Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J 2003 17 : 1871 85.
13. DePaulis A, Stellato C, Cirillo R. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992 99 : 723 8.
14. Zuberbier T, Chong SU, Grunow K et al. The ascomycin macrolactam pimecrolimus (Elidel®, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001 108 : 275 80.
15. Hultsch T, Müller KD, Meingassner JG et al. Ascomycin macrolactam derivative SZD ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin- dependent manner. Arch Dermatol Res 1998 290 : 501 7.
16. Ständer S, Luger T, Metze D. Effective treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001 44 : 471 8.
17. Ständer S, Moormann C, Schumacher M et al. Expression of vanilloid receptor subtype 1 (VR1) in cutaneous sensory nerve fibers, mast cells and epithelial cells of appendage structures. Exp Dermatol 2004 13 : 129 39.